Multiple myeloma is a heterogeneous haematological disease that originates from the bone marrow and is characterized by the monoclonal expansion of malignant plasma cells. Despite novel therapies, multiple myeloma remains clinically challenging. A common feature among patients with poor prognosis is the increased activity of the epigenetic silencer EZH2, which is the catalytic subunit of the PRC2. Interestingly, the recruitment of PRC2 lacks sequence specificity and, to date, the molecular mechanisms that define which genomic locations are destined to PRC2-mediated silencing remain unknown. The presence of a lncRNA-binding pocket on EZH2 suggests that lncRNAs could potentially mediate PRC2 recruitment to specific genomic regions. Here, we coupled RIP-seq, RNA-Seq and ChIP-seq analysis of human multiple myeloma primary cells and cell lines to identify potential lncRNA partners to EZH2. We found that the lncRNA plasmacytoma variant translocation 1 (PVT1) directly interacts with EZH2 and is overexpressed in patients with a poor prognosis. Moreover, genes predicted to be targets of PVT1 exhibited H3K27me3 enrichment and were associated with pro-apoptotic and tumour suppressor functions. In fact, PVT1 inhibition independently promotes the expression of the PRC2 target genes ZBTB7C, RNF144A and CCDC136. Altogether, our work suggests that PVT1 is an interacting partner in PRC2-mediated silencing of tumour suppressor and pro-apoptotic genes in multiple myeloma, making it a highly interesting potential therapeutic target.
Figures & Tables
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.